186 related articles for article (PubMed ID: 35943667)
1. Validation and predictive capacity of a Dutch version of the FLARE-RA questionnaire within the context of a TNFi-tapering trial.
Doumen M; Bertrand D; Pazmino S; De Cock D; Stouten V; Joly J; de Wergifosse I; Moeyersoons A; Westhovens R; Verschueren P
Clin Rheumatol; 2023 Jan; 42(1):39-45. PubMed ID: 35943667
[TBL] [Abstract][Full Text] [Related]
2. Prediction Aided Tapering In rheumatoid arthritis patients treated with biOlogicals (PATIO): protocol for a randomized controlled trial.
Messelink MA; van der Leeuw MS; den Broeder AA; Tekstra J; van der Goes MC; Heijstek MW; Lafeber F; Welsing PMJ
Trials; 2022 Jun; 23(1):494. PubMed ID: 35710576
[TBL] [Abstract][Full Text] [Related]
3. A multi-biomarker score measuring disease activity in rheumatoid arthritis patients tapering adalimumab or etanercept: predictive value for clinical and radiographic outcomes.
Bouman CAM; van der Maas A; van Herwaarden N; Sasso EH; van den Hoogen FHJ; den Broeder AA
Rheumatology (Oxford); 2017 Jun; 56(6):973-980. PubMed ID: 28339738
[TBL] [Abstract][Full Text] [Related]
4. The American English version of the validated French Flare Assessment in RA Questionnaire (FLARE-RA).
Barroso N; Woodworth TG; Furst DE; Guillemin F; Fautrel BJ; Borazan N; Kafaja S; Brook J; Elashoff DA; Ranganath VK
Clin Rheumatol; 2020 Jan; 39(1):189-199. PubMed ID: 31493148
[TBL] [Abstract][Full Text] [Related]
5. Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis-a proof of principle and exploratory trial: is dose tapering practical in good responders?
Ibrahim F; Lorente-Cánovas B; Doré CJ; Bosworth A; Ma MH; Galloway JB; Cope AP; Pande I; Walker D; Scott DL
Rheumatology (Oxford); 2017 Nov; 56(11):2004-2014. PubMed ID: 28968858
[TBL] [Abstract][Full Text] [Related]
6. Using real-world data to dynamically predict flares during tapering of biological DMARDs in rheumatoid arthritis: development, validation, and potential impact of prediction-aided decisions.
van der Leeuw MS; Messelink MA; Tekstra J; Medina O; van Laar JM; Haitjema S; Lafeber F; Veris-van Dieren JJ; van der Goes MC; den Broeder AA; Welsing PMJ
Arthritis Res Ther; 2022 Mar; 24(1):74. PubMed ID: 35321739
[TBL] [Abstract][Full Text] [Related]
7. Definition and construct validation of clinically relevant cutoffs on the Flare Assessment in Rheumatoid Arthritis (FLARE-RA) questionnaire.
Myasoedova E; De Thurah A; Erpelding ML; Schneeberger EE; Maribo T; Citera G; Davis JM; Matteson EL; Crowson CS; Fautrel B; Guillemin F
Semin Arthritis Rheum; 2020 Apr; 50(2):261-265. PubMed ID: 31526593
[TBL] [Abstract][Full Text] [Related]
8. Translation and cross-cultural adaptation into Italian of the self-administered FLARE-RA questionnaire for rheumatoid arthritis.
Ughi N; Schioppo T; Scotti I; Merlino V; Murgo A; De Lucia O; Fautrel B; Guillemin F; Christensen R; Ingegnoli F
Reumatismo; 2020 Apr; 72(1):21-30. PubMed ID: 32292018
[TBL] [Abstract][Full Text] [Related]
9. Flare Rate in Patients with Rheumatoid Arthritis in Low Disease Activity or Remission When Tapering or Stopping Synthetic or Biologic DMARD: A Systematic Review.
Kuijper TM; Lamers-Karnebeek FB; Jacobs JW; Hazes JM; Luime JJ
J Rheumatol; 2015 Nov; 42(11):2012-22. PubMed ID: 26428204
[TBL] [Abstract][Full Text] [Related]
10. A real-world 2-year prospective study of medication tapering in patients with well-controlled rheumatoid arthritis within the rheumatoid arthritis medication tapering (RHEUMTAP) cohort.
Tageldin M; Wilson N; Yin Y; Sharma TS
Rheumatology (Oxford); 2023 Oct; 62(Suppl_4):iv8-iv13. PubMed ID: 37855679
[TBL] [Abstract][Full Text] [Related]
11. Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
Verhoef LM; van den Bemt BJ; van der Maas A; Vriezekolk JE; Hulscher ME; van den Hoogen FH; Jacobs WC; van Herwaarden N; den Broeder AA
Cochrane Database Syst Rev; 2019 May; 5(5):CD010455. PubMed ID: 31125448
[TBL] [Abstract][Full Text] [Related]
12. Circulating calprotectin (S100A8/A9) is higher in rheumatoid arthritis patients that relapse within 12 months of tapering anti-rheumatic drugs.
de Moel EC; Rech J; Mahler M; Roth J; Vogl T; Schouffoer A; Goekoop RJ; Huizinga TWJ; Allaart CF; Toes REM; Schett G; van der Woude D
Arthritis Res Ther; 2019 Dec; 21(1):268. PubMed ID: 31805992
[TBL] [Abstract][Full Text] [Related]
13. Impact of flare on radiographic progression after etanercept continuation, tapering or withdrawal in patients with rheumatoid arthritis.
Smolen JS; Pedersen R; Jones H; Mahgoub E; Marshall L
Rheumatology (Oxford); 2020 Jan; 59(1):153-164. PubMed ID: 31257453
[TBL] [Abstract][Full Text] [Related]
14. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
[TBL] [Abstract][Full Text] [Related]
15. Advanced machine learning for predicting individual risk of flares in rheumatoid arthritis patients tapering biologic drugs.
Vodencarevic A; Tascilar K; Hartmann F; Reiser M; Hueber AJ; Haschka J; Bayat S; Meinderink T; Knitza J; Mendez L; Hagen M; Krönke G; Rech J; Manger B; Kleyer A; Zimmermann-Rittereiser M; Schett G; Simon D;
Arthritis Res Ther; 2021 Feb; 23(1):67. PubMed ID: 33640008
[TBL] [Abstract][Full Text] [Related]
16. Definition of rheumatoid arthritis flare based on SDAI and CDAI.
Konzett V; Kerschbaumer A; Smolen JS; Kristianslund EK; Provan SA; Kvien TK; Aletaha D
Ann Rheum Dis; 2024 Jan; 83(2):169-176. PubMed ID: 37890977
[TBL] [Abstract][Full Text] [Related]
17. Effect of tapered versus stable treatment with tumour necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial.
Lillegraven S; Paulshus Sundlisæter N; Aga AB; Sexton J; Olsen IC; Lexberg ÅS; Madland TM; Fremstad H; Høili CA; Bakland G; Spada C; Haukeland H; Hansen IM; Moholt E; Uhlig T; Solomon DH; van der Heijde D; Kvien TK; Haavardsholm EA
Ann Rheum Dis; 2023 Nov; 82(11):1394-1403. PubMed ID: 37607809
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of self-report questionnaires for assessing rheumatoid arthritis activity: a cross-sectional study of RAPID3 and RADAI5 and flare detection in 200 patients.
Bossert M; Prati C; Vidal C; Bongain S; Toussirot E; Wendling D
Joint Bone Spine; 2012 Jan; 79(1):57-62. PubMed ID: 21550283
[TBL] [Abstract][Full Text] [Related]
19. Tapering glucocorticoids and risk of flare in rheumatoid arthritis on biological disease-modifying antirheumatic drugs (bDMARDs).
Adami G; Fassio A; Rossini M; Bertelle D; Pistillo F; Benini C; Viapiana O; Gatti D
RMD Open; 2023 Jan; 9(1):. PubMed ID: 36599630
[TBL] [Abstract][Full Text] [Related]
20. Comparing a tapering strategy to the standard dosing regimen of TNF inhibitors in rheumatoid arthritis patients with low disease activity.
Plasencia C; Wolbink G; Krieckaert CL; Kneepkens EL; Turk S; Jurado T; Martínez-Feito A; Navarro-Compán V; Bonilla G; Villalba A; Peiteado D; Nuño L; Martín-Mola E; Nurmohamed MT; van der Kleij D; Rispens T; Pascual-Salcedo D; Balsa A
Clin Exp Rheumatol; 2016; 34(4):655-62. PubMed ID: 27214767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
